In this issue:
IMbrave150: atezolizumab plus bevacizumab improves QoL
Front-line lenvatinib delays functional deterioration in unresectable HCC
Shorter interval screening aids early detection of liver cancer
Biopsy for histological confirmation of advanced HCC
Liver cancer mortality disproportionate in Australian Indigenous people
ORIENT-32: Sintilimab plus IBI305 for unresectable HBV-associated HCC
Molecular characterisation of HCC in patients with non-alcoholic steatohepatitis
SBRT may be an option for small HCC lesions not amenable to curative interventions
No benefit to atezolizumab plus bevacizumab in fibrolamellar HCC
EDT ± everolimus fails to demonstrate activity in advanced fibrolamellar HCC
Please login below to download this issue (PDF)